Galapagos Reports New Post-Hoc Analyses from P-III SELECTION Program of Filgotinib to Treat Ulcerative Colitis

Shots:

• The P-III SELECTION trial comprises 2 induction trials & a maintenance trial evaluating filgotinib (200/100 mg) vs PBO in adult patients with active UC
• Induction studies results: improvements in PROs of SF & RB in biologic-naïve & biologic-experienced patients (200mg dose). In induction study A & B (18.8% vs 9.5% & 10.7% vs 4.2%) patients achieved a composite score of RB & SF as early as 9 & 7 day respectively
• In maintenance study, patients demonstrated CS-free remission @58wks., CS free in 6 & 8mos. (27% & 22% vs 6% & 6%). The safety analysis from all studies showed that the results are consistent with original induction & maintenance trials & was well tolerated

Click here to read full press release/ article | Ref: Globe Newswire | Image: Made in